An Abvd-Based Approach Confers Superior Outcomes For Adolescent And Young Adult Patients Compared To Other Adults With Advanced Classical Hodgkin Lymphoma

Combination chemotherapy with ABVD is widely used as first line therapy for adult classical Hodgkin lymphoma (cHL). However, for patients in the Adolescent and Younger Adult (AYA) age group, there is no consensus regarding preferred upfront therapy and diverse approaches have been used. Given this, we sought to assess the suitability of ABVD for AYA patients by undertaking a comparative analysis of outcomes for AYA patients and other adults treated at a single institution employing an ABVD-based approach.